Roivant Sciences (NASDAQ: ROIV) insider details large option exercises, sales

Rhea-AI Filing Summary

Roivant Sciences director Vivek Ramaswamy reported large stock option exercises and related share sales in December 2025. On 12/11, 12/12 and 12/15, he exercised options at $12.68 per share to acquire 1,869,691, 4,672,724 and 832,453 common shares, respectively. On those same dates he sold 774,142, 1,975,858 and 353,745 shares at weighted average prices of $21.64, $21.96 and $22.05, and additional shares were disposed of through issuer net settlement to cover option exercise costs.

After these transactions, he beneficially owned 33,653,755 common shares directly and 13,357,857 shares indirectly through his spouse. The exercised options would have expired in March 2026 if not exercised and arise from awards that began vesting on December 27, 2019.

Insights

Equity compensation and insider-transactions analyst

Ramaswamy exercised near-expiry options at $12.68 and sold shares around $22 while retaining a large Roivant Sciences stake.

Director Vivek Ramaswamy exercised stock options with a strike price of $12.68 on 12/11/2025, 12/12/2025 and 12/15/2025, acquiring 1,869,691, 4,672,724 and 832,453 common shares. These options were part of awards that began vesting on December 27, 2019 and would have expired in March 2026 if not exercised, which helps explain the timing.

On the same dates, he reported open-market sales of 774,142, 1,975,858 and 353,745 shares at weighted average prices of $21.64, $21.96 and $22.05. Footnotes state that each reported price reflects multiple transactions within disclosed ranges (for example, from $21.35 to $22.05). Additional shares (1,095,550, 2,696,866 and 478,708) were net settled by the issuer to satisfy option exercise prices.

Following all reported transactions, Ramaswamy held 33,653,755 common shares directly and 13,357,857 shares indirectly through his spouse. This indicates that, despite significant monetization of options and sales around the low‑$20 range, he continues to report a substantial ownership position in Roivant Sciences Ltd..

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ramaswamy Vivek

(Last) (First) (Middle)

C/O STEVE ROBERTS

700 PENNSYLVANIA AVE., SE STE. 440

(Street)

WASHINGTON DC 20003

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Roivant Sciences Ltd. [ ROIV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
12/11/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	12/11/2025		M		1,869,691	A	$12.68	35,523,447	D
Common Shares	12/11/2025		S		774,142	D	$21.64(1)	34,749,305	D
Common Shares	12/11/2025		J		1,095,550(2)	D	$21.64(1)	33,653,755	D
Common Shares	12/12/2025		M		4,672,724	A	$12.68	38,326,479	D
Common Shares	12/12/2025		S		1,975,858	D	$21.96(3)	36,350,621	D
Common Shares	12/12/2025		J		2,696,866(2)	D	$21.96(3)	33,653,755	D
Common Shares	12/15/2025		M		832,453	A	$12.68	34,486,208	D
Common Shares	12/15/2025		S		353,745	D	$22.05(4)	34,132,463	D
Common Shares	12/15/2025		J		478,708(2)	D	$22.05(4)	33,653,755	D
Common Shares								13,357,857(5)	I	Spousal

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$12.68	12/11/2025		M			1,869,691(7)	(6)	03/31/2026	Common Stock	1,869,691	$0	27,655,404	D
Stock Option (Right to Buy)	$12.68	12/12/2025		M			4,672,724(7)	(6)	03/31/2026	Common Stock	4,672,724	$0	22,982,680	D
Stock Option (Right to Buy)	$12.68	12/15/2025		M			832,453(7)	(6)	03/31/2026	Common Stock	832,453	$0	22,150,227	D

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.35 to $22.05, inclusive. The reporting person undertakes to provide to Roivant Sciences Ltd., any security holder of Roivant Sciences Ltd., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Form 4.

2. Represents the "net settlement" by the Issuer of options previously granted to the reporting person in order to satisfy the exercise price applicable to such options.

3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.65 to $22.13, inclusive.

4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.88 to $22.49, inclusive.

5. Represents the quantity of shares held indirectly only.

6. Award of stock options to purchase Common Shares with a vesting commencement date of December 27, 2019. These options vest and become exercisable (i) 25% on the first anniversary of the applicable vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject generally to the reporting person's continuous service through each vesting date (unless otherwise provided in the applicable award documentation).

7. All options exercised by the reporting person would have expired in March 2026 if not exercised.

	/s/ Stephen Roberts, as Attorney-in-Fact for Vivek Ramaswamy	12/15/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Roivant Sciences (ROIV) director Vivek Ramaswamy report?

He reported multiple December 2025 transactions, including exercising stock options at $12.68 per share and selling common shares at weighted average prices of $21.64, $21.96 and $22.05.

How many Roivant Sciences (ROIV) shares did Vivek Ramaswamy acquire through option exercises?

He exercised options on 12/11, 12/12 and 12/15 to acquire 1,869,691, 4,672,724 and 832,453 Roivant Sciences common shares, respectively, all at an exercise price of $12.68 per share.

How many Roivant Sciences (ROIV) shares did Vivek Ramaswamy sell and at what prices?

He sold 774,142, 1,975,858 and 353,745 common shares on 12/11, 12/12 and 12/15, at weighted average prices of $21.64, $21.96 and $22.05, respectively, with actual trades occurring within disclosed price ranges.

What is Vivek Ramaswamys Roivant Sciences (ROIV) ownership after these transactions?

After the reported exercises and sales, he beneficially owned 33,653,755 Roivant Sciences common shares directly and an additional 13,357,857 shares indirectly through his spouse.

What are the key terms of the Roivant Sciences stock options exercised by Vivek Ramaswamy?

The exercised options had an exercise price of $12.68 per share, relate to awards with a vesting commencement date of December 27, 2019, and would have expired in March 2026 if not exercised.

What does weighted average price mean in Vivek Ramaswamys Roivant Sciences share sales?

For each sale date, the reported price is a weighted average across multiple trades; for example, one footnote states shares were sold at prices ranging from $21.35 to $22.05, with the single figure reflecting the volume-weighted price.

What is the net settlement mentioned in the Roivant Sciences (ROIV) Form 4?

Footnote (2) explains that certain reported dispositions represent net settlement, where Roivant Sciences withheld shares otherwise issuable upon option exercise to satisfy the applicable exercise price.